Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention

BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro(®)) therapy affects long-term clinical outcomes of Korean...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Korean J Intern Med
Autores principales: Sim, Doo Sun, Jeong, Myung Ho, Kim, Weon, Rhew, Jay Young, Yum, Ju Hyup, Kim, Ju Han, Cho, Jeong Gwan, Ahn, Young Keun, Park, Jong Chun, Ahn, Byoung Hee, Kim, Sang Hyung, Kang, Jung Chaee
Formato: Artigo
Lenguaje:Inglês
Publicado: Korean Association of Internal Medicine 2003
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4531627/
https://ncbi.nlm.nih.gov/pubmed/14619381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2003.18.3.129
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares